Skip to Main Content

Dear Acting Secretary Speer,

As you know, the United States must prepare for future outbreaks of the Zika virus, but a high-stakes debate has erupted over a deal the federal government may strike with a private company to develop a vaccine. As acting secretary of the US Army, you have an opportunity — and responsibility — to find a workable solution.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED
  • Congenital ZIKV syndrome does not appear to be associated with maternal disease severity, ZIKV-RNA load at time of infection or existence of prior dengue antibodies.
    131 ZIKV-PCR positive pregnant women were scored for clinical disease severity, 6 (4.6%) had mild disease, 98 (74.8%) had moderate disease and 27 (20.6%) severe manifestations of ZIKV infection. There were 58 (46.4%) abnormal outcomes with 9 fetal losses (7.2%) in 125 pregnancies. No associations were found between: disease severity and abnormal outcomes (p=0.961; OR:1.00; 95%CI: 0.796- 1.270); disease severity and viral load (p = 0.994); viral load and adverse outcomes (p=0.667; OR:1.02; 95%CI: 0.922- 1.135); or existence of prior dengue antibodies (88% subjects) with severity score, ZIKV-RNA load or adverse outcomes (p = 0.667; OR 0.78; 95%CI : 0.255 – 2.397).
    CONCLUSIONS:
    Congenital ZIKV syndrome does not appear to be associated with maternal disease severity, ZIKV-RNA load at time of infection or existence of prior dengue antibodies.
    https://www.ncbi.nlm.nih.gov/pubmed/28535184

Comments are closed.